Genenta Science S.p.A. (GNTA)

NASDAQ: GNTA · IEX Real-Time Price · USD
5.13
+0.32 (6.58%)
Nov 25, 2022 4:00 PM EDT - Market closed
6.58%
Market Cap 87.44M
Revenue (ttm) n/a
Net Income (ttm) -3.78M
Shares Out 18.22M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,042
Open 4.9
Previous Close 4.81
Day's Range 4.9 - 5.15
52-Week Range 3.9 - 13.13
Beta n/a
Analysts Buy
Price Target 23.12 (+351.0%)
Earnings Date n/a

About GNTA

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company... [Read more]

Industry Biotechnology
IPO Date Dec 15, 2021
Country Italy
Stock Exchange NASDAQ
Ticker Symbol GNTA
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for GNTA stock is "Buy." The 12-month stock price forecast is 23.12, which is an increase of 351.03% from the latest price.

Price Target
$23.12
(351.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblas...

• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclinic...

2 weeks ago - GlobeNewsWire

Genenta Provides First Half 2022 Business Update and Financial Results

MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), (“Genenta” or the “Company”), a clinical stage immuno-oncology company developing a cell-based platform harne...

1 month ago - GlobeNewsWire

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoiet...

1 month ago - GlobeNewsWire

Genenta to Present at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoie...

2 months ago - GlobeNewsWire

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets

4 months ago - GlobeNewsWire

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno...

6 months ago - GlobeNewsWire

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Extensive experience in business development with AstraZeneca and GSK Extensive experience in business development with AstraZeneca and GSK

6 months ago - GlobeNewsWire

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...

6 months ago - GlobeNewsWire

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial

6 months ago - GlobeNewsWire

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Initial evidence of potential to modulate tumor microenvironment Initial evidence of potential to modulate tumor microenvironment

6 months ago - GlobeNewsWire

Genenta Announces Nomination of Mark A. Sirgo as Chair

35 years industry experience including as CEO and founder of public company

6 months ago - GlobeNewsWire

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

*** David Reardon, Luigi Naldini, Brad Loncar *** *** David Reardon, Luigi Naldini, Brad Loncar ***

7 months ago - GlobeNewsWire

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma...

Data to be presented at the 2022 annual meeting of American Association for Cancer Research Data to be presented at the 2022 annual meeting of American Association for Cancer Research

8 months ago - GlobeNewsWire

Genenta to Participate at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immun...

9 months ago - GlobeNewsWire

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cel...

11 months ago - GlobeNewsWire

Genenta Announces Pricing of Upsized Initial Public Offering

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene t...

11 months ago - GlobeNewsWire